Panel · Use case · Regulatory

New Indication Benefit-Risk Review.

LiveBenefit-Risk Panel

Does the benefit-risk balance of this product in a new indication clear the bar set by current treatments for that condition?

DecisionWhether the balance clears the bar of current treatments

FunctionsRegulatory, medical, safety, evidence

ReaderRegulatory and medical leads

Not askedA regulatory submission

DepthStandard, four seats

New Indication Benefit-Risk Review is a ready-made use case for Regulatory. It ships under the Benefit-Risk Panel template.

For regulatory leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Does the benefit-risk balance of this product in a new indication clear the bar set by current treatments for that condition?

Who weighs

FDA’s benefit-risk guidance starts from the severity of the condition and how well current treatments meet patient needs. The seats weigh the new indication against that.

Seat	What it weighs	What it works from
Regulatory Strategist	Whether the balance would meet the standard the agency applies for this indication.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}	FDA’s benefit-risk guidance.
Global Medical Affairs Director	Whether the benefit matters to patients against what is available.	Guidelines and clinical evidence.
Head of Pharmacovigilance	The size and seriousness of the risks, and how they can be managed.^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).}	Safety data and risk minimization options.
Global Value & Evidence Lead	How certain each effect is and what would change it.	The evidence base.

What the assessment does

The comparator is current treatment. Benefit is read against what patients can already have, not against no treatment. The effects table names the comparator for each row.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}

Some uncertainty must be accepted. In serious conditions with few alternatives, FDA’s recap says some uncertainty is inevitable. The report states which uncertainties are acceptable and why.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}

No composite score. Benefits and risks are shown separately and weighed in words. Importance is high, medium or low and is labeled analyst judgment.^{3ISPOR Task Force. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report. Value in Health, 2023.}

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

The comparator the report uses reflects current standard of care.
The safety database is large enough to show the risks that matter.
Risk minimization measures will be followed in practice.

Standards, guidance and sources

Frame

FDA, benefit-risk assessment for new drug and biologic products.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}
FDA, REMS program.^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).}
ISPOR good practices report on quantitative benefit-risk assessment.^{3ISPOR Task Force. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report. Value in Health, 2023.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any effect without a source, any benefit with no stated comparator, and any risk the seats weighed differently by a large margin.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not prepare the benefit-risk section of a submission.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Read on 9 October 2026.
[2] U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Read on 9 October 2026 at its earlier address.
[3] ISPOR Task Force. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report. Value in Health, 2023. News release and abstract page only.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.